Literature DB >> 11703107

Novel approaches to polynuclear platinum pro-drugs. Selective release of cytotoxic platinum-spermidine species through hydrolytic cleavage of carbamates.

A Hegmans1, Y Qu, L R Kelland, J D Roberts, N Farrell.   

Abstract

BBR3464 is a novel trinuclear platinum drug currently in Phase II clinical trials. Polyamine-bridged dinuclear platinum compounds as represented by [[trans-Pt(NH(3))(2)Cl](2)-mu-spermidine-N(1),N(8)]Cl(3) (1) are highly interesting second-generation analogues of BBR3464 because the hydrogen-bonding and electrostatic contributions of the central platinum-amine group in BBR3464 are replicated by the free, noncoordinated "central" quaternary nitrogens of the linear polyamine linker while the presence of two separate Pt-Cl bonds maintains the bifunctional binding mode on the DNA adducts. Preclinical investigations confirm the potency of these species with cytotoxicity in the nanomolar range. This remarkable potency results in a relatively narrow therapeutic index. To enhance the therapeutic index of these drugs, we investigated the potential for "pro-drug" delivery of less toxic and better tolerated derivatives such as the compounds [[trans-Pt(NH(3))(2)Cl](2)-mu-N(4)-R-spermidine-N(1),N(8)]Cl(2) where N(4)-R represents BOC (tert-butyl), CBz (benzyl), and Fmoc (fluorenylmethyl) carbamate blocking groups, 2-4, respectively. The bulky Fmoc derivative showed evidence for conformational isomers by (1)H NMR spectroscopy due to the inequivalence of the two n-propyl and n-butyl side chains of the spermidine moiety. The rate constants for hydrolysis and release of 1 were calculated. Release of cytotoxic 1 at physiologically relevant pH followed the order 4 > 2 > 3. The calculated values for 4 (pH 5, 6.0(+/-3.9) x 10(-10) s(-1); pH 6, 6.5(+/-0.2) x 10(-9) s(-1); pH 7, 6.0(+/-0.2) x 10(-8) s(-1); pH 8, 1.6(+/-0.1) x 10(-7) s(-1)) show a more pronounced pH dependence compared to 2 (pH 5, 4.6(+/-0.1) x 10(-8) s(-1); pH 6, 4.2(+/-0.1) x 10(-8) s(-1); pH 7, 3.2(+/-0.1) x 10(-8) s(-1)). Preliminary biological assays of cellular uptake and cytotoxicity confirm the utility of the pro-drug concept. While blocked-polyamine compounds such as 2-4 are, in general, 2-3 orders of magnitude less cytotoxic than 1, there is significant cell type variability. Specifically, the Fmoc derivative 4 showed significantly enhanced cytotoxicity warranting further study of the pro-drug concept for greater selectivity and/or oral delivery.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11703107     DOI: 10.1021/ic010509a

Source DB:  PubMed          Journal:  Inorg Chem        ISSN: 0020-1669            Impact factor:   5.165


  5 in total

Review 1.  Recent advances in the development of polyamine analogues as antitumor agents.

Authors:  Robert A Casero; Patrick M Woster
Journal:  J Med Chem       Date:  2009-08-13       Impact factor: 7.446

2.  Novel palladium(II) complexes containing a sulfur ligand: structure and biological activity on HeLa cells.

Authors:  EnJun Gao; Feng Guan; XiaNan Gao; MingChang Zhu; Lei Liu; ChuanSheng Wang; WanZhong Zhang; YaGuang Sun
Journal:  J Biol Inorg Chem       Date:  2011-10-11       Impact factor: 3.358

3.  Factors affecting DNA-DNA interstrand cross-links in the antiparallel 3'-3' sense: a comparison with the 5'-5' directional isomer.

Authors:  Rasha A Ruhayel; Joseph J Moniodis; Xiaohong Yang; Jana Kasparkova; Viktor Brabec; Susan J Berners-Price; Nicholas P Farrell
Journal:  Chemistry       Date:  2009-09-21       Impact factor: 5.236

4.  Amide-based prodrugs of spermidine-bridged dinuclear platinum. Synthesis, DNA binding, and biological activity.

Authors:  Alexander Hegmans; Jana Kasparkova; Oldrich Vrana; Lloyd R Kelland; Viktor Brabec; Nicholas P Farrell
Journal:  J Med Chem       Date:  2008-03-14       Impact factor: 7.446

5.  In vitro and in vivo evaluation of a novel mitomycin nanomicelle delivery system.

Authors:  Hongmei Yang; Miao Wang; Yihe Huang; Qiaoyu Qiao; Chunjie Zhao; Min Zhao
Journal:  RSC Adv       Date:  2019-05-13       Impact factor: 3.361

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.